INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Reardon Andrew sold LGND

CLO & Secretary · LIGAND PHARMACEUTICALS INC · Common Stock

Side
SELL
Value
$5,232
Shares
17
Price
$307.74
Executed
Oct 2, 2026
Disclosed
Oct 6, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Oct 2 executedOct 6, 2026 disclosed

LGND · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $5K reported value · 0.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 38 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LGND

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M—
    5,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$39K
    120 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$162K
    522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    2
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M$261K
    5,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$87K
    283 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$25K
    80 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$152K
    490 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$218K
    708 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$102K
    320 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$89K
    280 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$126K
    403 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$64K
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$140K
    440 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$162K
    520 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$198K
    634 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$72K
    235 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    4
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$467K
    1,535 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    1
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$124K
    404 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    0
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M$18K
    340 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    4
    RA
    Reardon AndrewCLO & Secretary
    LGNDLIGAND PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$252K
    833 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001950232-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 2, 2026
    Published
    Oct 6, 2026
    Ingested by INSIDER
    Nov 5, 02:13 UTC
    Last re-read
    Nov 5, 02:13 UTC

    Extracted facts

    Filer
    Reardon Andrew
    Role
    CLO & Secretary
    Transaction
    Open-market saleAs filed: “S”
    Asset
    LIGAND PHARMACEUTICALS INC
    Ticker
    LGND
    Shares
    17
    Price per share
    $307.74
    Value
    $5,232
    Execution date (reported)
    Oct 2, 2026
    Owned after transaction
    31.9K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 17
    • Price: $307.74

    = $5,232

    What this establishes

    Reardon Andrew filed this Form 4 reporting a open-market sale of LGND on Oct 2, 2026. It became public on Oct 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    CLO & Secretary
    Reardon Andrewcik:0001950232
    Issuer
    LIGAND PHARMACEUTICALS INCcik:0000886163

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.